性饮食对沙特阿拉伯儿童 (婴儿至14岁) 耐性发作发作减少的影响:一个横截面研究
Leena R Baghdadi1, Renad A Alhomaidi2, Fatimah S Alhelal2
1Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Translational pediatrics
|October 10, 2023
概括
性饮食显示出治疗儿童耐火性的前景. 较高的饮食比例 (3:1, 4.5:1) 和体育活动改善了发作频率,而父母的教育和收入也影响了结果.
科学领域:
- 儿科神经学 儿科神经学
- 代谢疗法 代谢疗法
- 症管理 症管理
背景情况:
- 在儿童中,耐药性是由持续的残疾性发作所定义的,尽管有抗药物试验.
- 素饮食是全球难治性发作的一种成熟治疗方法,但在沙特阿拉伯未得到充分利用.
- 这项研究调查了性饮食的有效性和影响沙特儿童耐火性的因素.
研究的目的:
- 检查基因饮食暴露与儿科耐性发作频率降低之间的关系.
- 确定与改善儿童发作结果相关的因素.
- 评估饮食比例,体力活动和社会人口统计因素对控制的影响.
主要方法:
- 在沙特阿拉伯的利雅得国王法哈德医疗城进行了一项横截面研究.
- 审查了95名儿童 (10个月至14岁) 患有耐火性的医疗记录,这些儿童接受了性饮食.
- 通过电话采访收集家长的社会经济数据.
主要成果:
- 饮食比较高的性饮食 (3:1和4.5:1) 的儿童的发作频率下降 (高达44%).
- 一般性患者 (56.1%) 和门诊患者 (66.7%) 显示出最显著的发作结果改善.
- 较低发作改善与父母教育水平较低,收入较低,发作诊断年龄较晚 (>8岁) 有关.
结论:
- 性饮食是一种可行的,有前途的治疗儿科耐火性.
- 较高的性饮食比例和增加的体力活动与更好的控制相关.
- 父母的教育,收入和患者的流动性是影响治疗成功的重要因素.
更多相关视频
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
2.7K
05:54Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
Published on: June 13, 2016
17.3K
相关概念视频
01:08Antiepileptic Drugs: Sodium Channel Blockers
614
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
614
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
318
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
318
01:24Arteries of the Lower Limbs
194
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
194
01:17Antiepileptic Drugs: Calcium Channel Blockers
420
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
420
01:20Antiepileptic Drugs: Potassium Channel Activators
192
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
192
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
426
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
426